Skip to main content
SpringerLink
Log in

Quinolone antimicrobial agents: Adverse effects and bacterial resistance

  • Current Topic: Review
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Adverse effects, drug-drug interactions and bacterial resistance to the new quinolone antimicrobial agents are reviewed. Clinical adverse effects are reported to occur in 5–10% of patients, and include primarily gastrointestinal disturbances, central nervous system toxicity and rash. Laboratory abnormalities are reported to occur in 5–12% of patients, and include mild reversible elevations of transaminases. Quinolones are not recommended in persons whose bone growth is incomplete or in pregnant or nursing women because cartilage toxicity has been observed in juvenile beagles. Drug-drug interactions may occur between quinolones and theophylline, caffeine, and magnesium- or aluminium-containing compounds such as antacids and sucralfate. Bacterial resistance occurs by chromosomal mutations which alter the target enzyme DNA gyrase or decrease drug accumulation. Emergence of resistance during therapy is uncommon to date but can be problematic in infections withPseudomonas aeruginosa, Staphylococcus aureus and other bacteria for which the therapeutic index may be low. In summary, quinolones thus far have been well tolerated, but more experience is needed to determine the exact nature and extent of adverse effects and emergence of bacterial resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wang, C., Sabbaj, J., Corrado, M., Hoagland, V. World-wide clinical experience with norfloxacin: efficacy and safety. Scandinavian Journal of Infectious Diseases 1986, Supplement 48: 81–89.

    Google Scholar 

  2. Schacht, P., Arcieri, G., Branolte, J., Bruck, H., Chysky, V., Griffith, E., Gruenwaldt, G., Hullmann, R., Konopka, C. A., O'Brien, B., Rahm, V., Ryoki, T., Westwood, A., Weuta, H. Worldwide clinical data on efficacy and safety of ciprofloxacin. Infection 1988, 16, Supplement 1: 29–43.

    Article  PubMed  Google Scholar 

  3. Blomer, R., Bruch, K., Krauss, H., Wacheck, W. Safety of ofloxacin — adverse drug reactions reported during phase-II studies in Europe and in Japan. Infection 1986, 14, Supplement 4: 332–334.

    Article  Google Scholar 

  4. Koverech, A., Picari, M., Granata, F., Fostini, R., Toniolo, D., Recchia, G. Safety profile of ofloxacin: the Italian data base. Infection 1986, 14, Supplement 4: 335–337.

    Article  Google Scholar 

  5. Halkin, H. Adverse effects of the fluoroquinolones. Reviews of Infectious Diseases 1988, 10, Supplement 1: 258–261.

    Google Scholar 

  6. Arcieri, G., August, R., Becker, N., Doyle, C., Griffith, E., Gruenwaldt, G., Heyd, A., O'Brien, B. Clinical experience with ciprofloxacin in the USA. European Journal of Clinical Microbiology 1986, 5: 220–225.

    PubMed  Google Scholar 

  7. Corrado, M. L., Struble, W. E., Hesney, M. The tolerability profile of prophylactic norfloxacin in neutropenic patients. European Journal of Cancer and Clinical Oncology 1988, 24, Supplement 1: 29–33.

    Article  Google Scholar 

  8. Jungst, G., Mohr, R. Overview of postmarketing experience with ofloxacin in Germany. Journal of Antimicrobial Chemotherapy 1988, 22, Supplement C: 167–175.

    Google Scholar 

  9. Davies, B. I., Maesen, F. P. V., Teengs, J. P. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study. Journal of Antimicrobial Chemotherapy 1984, 14, Supplement C: 83–89.

    PubMed  Google Scholar 

  10. Simpson, K. J., Brodie, M. J. Convulsions related to enoxacin. Lancet 1985, ii: 161.

    Article  Google Scholar 

  11. Tsuji, A., Sato, H., Kume, Y., Tamai, I., Okezaki, E., Nagata, O., Kato, H. Inhibitory effects of quinolone antibacterial agents on τ-aminobutyric acid binding receptor sites in rat brain membranes. Antimicrobial Agents and Chemotherapy 1988, 32: 190–194.

    PubMed  Google Scholar 

  12. Hori, S., Kurioka, S., Matsuda, M., Shimada, J. Inhibitory effect of cephalosporins on τ-aminobutyric acid receptor binding in rat synaptic membranes. Antimicrobial Agents and Chemotherapy 1985, 27: 650–651.

    PubMed  Google Scholar 

  13. Wijnands, W. J. A., Vree, T. B., Van Herwaarden, C. L. A. The influence of quinolone derivatives on theophylline clearance. British Journal of Pharmacology 1986, 22: 677–683.

    Google Scholar 

  14. Niki, Y., Soejima, R., Kawane, H., Sumi, M., Umeki, S. New synthetic quinolone antibacterial agents and serum concentration of theophylline. Chest 1987, 92: 663–669.

    PubMed  Google Scholar 

  15. Gregoire, S. L., Grasela, T. H., Freer, J. P., Tack, K. J., Schentag, J. J. Inhibition of theophylline clearance by coadministered ofloxacin with alteration of theophylline effects. Antimicrobial Agents and Chemotherapy 1987, 31: 375–378.

    PubMed  Google Scholar 

  16. Bowles, S. K., Popovski, Z., Rybak, M. J., Beckman, H. B., Edewards, D. J. Effect of norfloxacin on theophylline pharmacokinetics at steady state. Antimicrobial Agents and Chemotherapy 1988, 32: 510–512.

    PubMed  Google Scholar 

  17. Aceto, M. D., Harris, L. S., Lesher, G. Y., Pearl, J., Brown, T. G. Pharmacologic studies with 7-benzyl-1-ethyl-1,4-dihydro-4-1,8-naphthyridine-3-carboxylic acid. Journal of Pharmacology and Experimental Therapeutics 1967, 158: 286–293.

    PubMed  Google Scholar 

  18. Handsfield, H. H., Judson, F. N., Holmes, K. K. Treatment of uncomplicated gonorrhea with rosoxacin. Antimicrobial Agents and Chemotherapy 1981, 20: 625–629.

    PubMed  Google Scholar 

  19. Romanowski, B., Austin, T. W., Pattison, F. L., Lawee, D., Portnoy, D., Givan, K. F., Li, E. L. F., Nguyen, K. B. Rosoxacin in the therapy of uncomplicated gonorrhea. Antimicrobial Agents and Chemotherapy 1984, 25: 455–457.

    PubMed  Google Scholar 

  20. Ball, P. Ciprofloxacin: an overview of adverse experiences. Journal of Antimicrobial Chemotherapy 1986, 18, Supplement D: 187–193.

    PubMed  Google Scholar 

  21. Jensen, T., Pedersen, S. S., Nielsen, C. H., Høiby, N., Koch, C. The efficacy and safety of ciprofloxacin and ofloxacin in chronicPseudomonas aeruginosa infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy 1987, 20: 585–594.

    PubMed  Google Scholar 

  22. Shelley, E. D., Shelley, W. B. The subcorneal pustular drug eruption: an example induced by norfloxacin. Cutis 1988, 42: 24–27.

    PubMed  Google Scholar 

  23. Arcieri, G., Griffin, E., Gruenwaldt, G., Heyd, A., O'Brien, B., Becker, N., August, R. Ciprofloxacin: an update on clinical experiences. American Journal of Medicine 1987, 82, Supplement 4A: 381–394.

    Google Scholar 

  24. Garlando, F., Tuber, M. G., Joos, B., Oelz, O., Luthy, R. Ciprofloxacin-induced hematuria. Infection 1985, 13: 177–178.

    Article  PubMed  Google Scholar 

  25. Rippelmeyer, D. J., Synhavsky, A. Ciprofloxacin and allergic interstitial nephritis. Annals of Internal Medicine 1988, 109: 170.

    Google Scholar 

  26. Boelaert, J., de Jaegere, P. P., Daneels, R., Schurgers, M., Bordts, B., van Landuyt, H. W. Case report of renal failure during norfloxacin therapy. Clinical Nephrology 1986, 25: 272.

    PubMed  Google Scholar 

  27. Staib, A. H., Harder, S., Mieke, S., Beer, C., Stille, W., Shah, P. Gyrase-inhibitors impair caffeine elimination in man. Methods and Findings in Experimental Clinical Pharmacology 1987, 9: 193–198.

    Google Scholar 

  28. Hoffken, G., Borner, K., Galtzel, P. D., Koeppe, P., Lode, H. Reduced enteral absorption of ciprofloxacin in the presence of antacids. European Journal of Clinical Microbiology 1985, 4: 345.

    Google Scholar 

  29. Preheim, L. C., Cuevas, T. A., Roccaforte, J. S., Mellencamp, M. A., Bittner, M. J. Ciprofloxacin and antacids. Lancet 1986, ii: 48.

    Article  Google Scholar 

  30. Fleming, L. W., Moreland, T. A., Stewart, W. K., Scott, A. C. Ciprofloxacin and antacids. Lancet 1986, ii: 294.

    Article  Google Scholar 

  31. Golper, T. A., Hartstein, A. I., Morthland, V. H., Christensen, J. M. Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Antimicrobial Agents and Chemotherapy 1987, 31: 1787–1790.

    PubMed  Google Scholar 

  32. Hoffken, G., Lode, H., Wiley, R., Glatzel, T. D., Sievers, D., Olschewski, T., Borner, K., Koeppe, T. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. Reviews of Infectious Diseases 1988, 10, Supplement 1: 138–139.

    PubMed  Google Scholar 

  33. Maesen, F. P. V., Davies, B. I., Geraedts, W. H., Sumajow, C. A. Ofloxacin and antacids. Journal of Antimicrobial Chemotherapy 1987, 19: 848–850.

    PubMed  Google Scholar 

  34. Parpia, S. H., Nix, D. E., Hejmanowski, L. G., Goldstein, H. R., Wilton, J. H., Schentag, J. J. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrobial Agents and Chemotherapy 1989, 33: 99–102.

    PubMed  Google Scholar 

  35. Rubinstein, E., Segev, S. Drug interactions of ciprofloxacin with other non-antibiotic agents. American Journal of Medicine 1987, 82, Supplement 4A: 119–123.

    PubMed  Google Scholar 

  36. Lode, H. Drug interactions with quinolones. Reviews of Infectious Diseases 1988, 10, Supplement 1: 132–136.

    Google Scholar 

  37. Avent, C. K., Krinsky, D., Kirklin, J. K., Bourge, R. C., Figg, W. D. Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine. American Journal of Medicine 1988, 85: 452–453.

    Article  PubMed  Google Scholar 

  38. Elston, R. A., Taylor, J. Possible interaction of ciprofloxacin with cyclosporin A. Journal of Antimicrobial Chemotherapy 1988, 5: 679–680.

    Google Scholar 

  39. Ingham, B., Brentnall, D. W., Dale, E. A., McFadzean, J. A. Arthropathy induced by antibacterial fusedN-alkyl-4-pyridone-3-carboxylic acids. Toxicology Letters 1977, 1: 21–26.

    Article  Google Scholar 

  40. Tatsumi, H., Senda, H., Yatera, S., Takemoto, Y., Yamayoshi, M., Ohnishi, K. Toxicological studies on pipemidic acid. V. Effect on diarthodial joints of experimental animals. Journal of Toxicological Sciences 1987, 3: 357–367.

    Google Scholar 

  41. Christ, W., Lehnert, T., Ulbrich, B. Specific toxicologic aspects of quinolones. Reviews of Infectious Diseases 1988, 10, Supplement 1: 141–146.

    Google Scholar 

  42. Schluter, G. Ciprofloxacin: review of potential toxicologic effects. American Journal of Medicine 1987, 82, Supplement 4A: 91–93.

    Google Scholar 

  43. Stahlmann, R., Blankenburg, G., Neubert, D. Studies on cartilage formation and differentiation in limbbud culture in the presence of nalidixic acid, ofloxacin, and ciprofloxacin. Reviews of Infectious Discases 1988, 10, Supplement 1: 147.

    Google Scholar 

  44. Schaad, U. B., Wedgwood-Krucko, J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection 1987, 15: 165–168.

    Article  PubMed  Google Scholar 

  45. Bailey, R. R., Kirk, J. A., Peddie, B. A. Norfloxacininduced rheumatic disease. New Zealand Medical Journal 1983, 96: 590.

    PubMed  Google Scholar 

  46. Alfaham, M., Holt, M. E., Goodchild, M. C. Arthropathy in a patient with cystic fibrosis taking ciprofloxacin. British Medical Journal 1987, 295: 699.

    PubMed  Google Scholar 

  47. Monk, J. P., Campoli-Richards, D. M. Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1987, 33: 346–391.

    PubMed  Google Scholar 

  48. McEwan, S. R., Davey, P. G. Ciprofloxacin and tenosynovitis. Lancet 1988, ii: 900.

    Article  Google Scholar 

  49. Wolfson, J. S., Hooper, D. C. Norfloxacin: a new targeted fluoroquinolone antimicrobial agent. Annals of Internal Medicine 1988, 108: 238–251.

    PubMed  Google Scholar 

  50. Schaeffer, A. J. Multiclinic study of norfloxacin for treatment of complicated or uncomplicated urinary tract infections. American Journal of Medicine 1987, 82, Supplement 6B: 53–64.

    Article  Google Scholar 

  51. Swanson, B. N., Boppana, V. K., Vlasses, P. H., Rotmensch, H. H., Ferguson, R. K. Norfloxacin disposition after sequentially increasing oral doses. Antimicrobial Agents and Chemotherapy 1983, 23: 284–288.

    PubMed  Google Scholar 

  52. Thorsteinsson, S. B., Bergan, T., Oddsdottir, S., Rohwedder, R., Holm, R. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy 1986, 32: 408–417.

    PubMed  Google Scholar 

  53. Hussy, P., Maass, G., Tummler, B., Grosse, F., Schomburg, V. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase α-primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrobial Agents and Chemotherapy 1986, 29: 1073–1078.

    PubMed  Google Scholar 

  54. Shen, L. L., Pernet, A. G. Mechanisms of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drug is DNA. Proceedings of the National Academy of Sciences of the USA 1985, 82: 307–311.

    PubMed  Google Scholar 

  55. McQueen, C. A., Williams, G. M. Effects of quinolone antibiotics in tests for genotoxicity. American Journal of Medicine 1987, 82, Supplement 4A: 94–96.

    Google Scholar 

  56. Mitelman, F., Kolnig, A.-M., Strombeck, B., Norrby, R., Kromann-Andersen, B., Sommer, P., Wadstein, J. No cytogenetic effects of quinolone treatment in humans. Antimicrobial Agents and Chemotherapy 1988, 32: 936–937.

    PubMed  Google Scholar 

  57. Corrado, M. L., Struble, W. E., Peter, C., Hoagland, V., Sabbaj, J. Norfloaxacin: review of safety studies. American Journal of Medicine 1987, 82, Supplement 6B: 22–27.

    Article  PubMed  Google Scholar 

  58. Medical Letter on Drugs and Therapeutics: Norfloxacin (Noroxin). 1987, 29: 25–27.

  59. Medical Letter on Drugs and Therapeutics: Ciprofloxacin. 1988, 30: 11–13.

  60. Barriere, S. L. Economic impact of ciprofloxacin: a pharmacist's view. American Journal of Medicine 1987, 82, Supplement 4A: 387–390.

    Article  Google Scholar 

  61. Quintiliani, R., Cooper, B. W., Briceland, L. L., Nightingale, C. H. Economic impact of streamlining antibiotic administration. American Journal of Medicine 1987, 82, Supplement 4A: 391–394.

    PubMed  Google Scholar 

  62. Ramirez-Ronda, C., Colon, M., Saavedra, S., Sabbaj, J., Corrado, M. L. Treatment of urinary tract infection with norfloxacin. Analysis of cost. American Journal of Medicine 1987, 82, Supplement 6B: 75–78.

    Article  PubMed  Google Scholar 

  63. Henry, N. K., Schultz, H. J., Grubbs, N. C., Muller, S. M., Ilstrup, D. M., Wilson, W. R. Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women. Journal of Antimicrobial Chemotherapy 1986, 18, Supplement D: 103–106.

    Google Scholar 

  64. Pichler, H., Diridl, G. Wolf, D. Ciprofloxacin in the treatment of acute bacterial diarrhea: a double-blind study. European Journal of Clinical Microbiology 1986, 5: 241–243.

    PubMed  Google Scholar 

  65. Roddy, R. E., Handsfield, H. H., Hook, E. W. Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men. Antimicrobial Agents and Chemotherapy 1986, 30: 267–269.

    PubMed  Google Scholar 

  66. Fong, I. W., Linton, W., Simbul, M., Thorup, R., McLaughlin, B., Rahm, V., Quinn, P. A. Treatment of nongonococcal urethritis with ciprofloxacin. American Journal of Medicine 1987, 82, Supplement 4A: 311–316.

    PubMed  Google Scholar 

  67. Ramirez-Ronda, C. H., Saavedra, S., Rivera-Vazquez, C. R. Comparative double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections. American Journal of Medicine 1987, 82, Supplement 4A: 220–223.

    PubMed  Google Scholar 

  68. Renkonen, O.-V., Sivonen, A., Visakorpi, R. Effect of ciprofloxacin on carrier rate ofNeisseria meningitidis in army recruits in Finland. Antimicrobial Agents and Chemotherapy 1987, 31: 962–963.

    PubMed  Google Scholar 

  69. Self, P. L., Zeluff, B. A., Sollo, D., Gentry, L. O. Use of ciprofloxacin in the treatment of serious skin and skin structure infections. American Journal of Medicine 1987, 82, Supplement 4A: 239–241.

    Article  PubMed  Google Scholar 

  70. Wollschlager, C. M., Raoof, S., Khan, F. A., Guarneri, J. J., LaBombardi, V., Afzal, Q. Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. American Journal of Medicine 1987, 82, Supplement 4A: 164–168.

    PubMed  Google Scholar 

  71. Allais, J. M., Preheim, L. C., Cuevas, T. A., Roccaforte, J. S., Mellencamp, M. A., Bittner, M. J. Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections. Antimicrobial Agents and Chemotherapy 1988, 32: 1327–1330.

    PubMed  Google Scholar 

  72. Tsuei, S. E., Darragh, A. S., Brick, I. Pharmacokinetics and tolerance of enoxacin in healthy volunteers administered at a dosage of 400mg twice daily for 14 days. Journal of Antimicrobial Chemotherapy 1984, 14, Supplement C: 71–74.

    Google Scholar 

  73. Urinary Tract Infection Study Group Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infections. Journal of Infectious Diseases 1987, 155: 170–177.

    Google Scholar 

  74. Wistrom, J., Norrby, S. R., Burman, L. G., Lundholm, R., Jellheden, B., Englund, G. Norfloxacin versus placebo for prophylaxis against travellers' diarrhea. Journal of Antimicrobial Chemotherapy 1987, 20: 563–574.

    PubMed  Google Scholar 

  75. Piffaretti, J. C., Demarta, A., Leidi-Bulla, L., Peduzzi, R. In vitro emergence ofEscherichia coli andPseudomonas aeruginosa strains resistant to norfloxacin and nalidixic acid. European Journal of Clinical Microbiology 1983, 2: 600–601.

    PubMed  Google Scholar 

  76. Wolfson, J. S., Hooper, D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrobial Agents and Chemotherapy 1985, 28: 581–586.

    PubMed  Google Scholar 

  77. Cullman, W., Stieglitz, M., Baars, B., Opferkuch, W. Comparative evaluation of recently developed quinolone compounds — with a note on the frequency of resistant mutants. Chemotherapy 1985, 31: 19–28.

    PubMed  Google Scholar 

  78. Smith, J. T. Frequency and expression of mutational resistance to the 4-quinolone antibacterials. Scandinavian Journal of Infectious Diseases 1986, Supplement 49: 115–123.

    Google Scholar 

  79. Chin, N.-X., Brittain, D. C., Neu, H. C. In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Antimicrobial Agents and Chemotherapy 1986, 29: 675–680.

    PubMed  Google Scholar 

  80. Fernandes, P. B., Hanson, C. W., Stamm, J. M., Vojtko, C., Shipkowitz, N. L., St. Martin, E. The frequency of in vitro resistance development to fluoroquinolones and the use of murine pyelonephritis model to demonstrate selection of resistance in vivo. Journal of Antimicrobial Chemotherapy 1987, 19: 449–465.

    PubMed  Google Scholar 

  81. Tenney, J. H., Maack, R. W., Chippendale, G. R. Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin agar. Antimicrobial Agents and Chemotherapy 1983, 23: 188–189.

    PubMed  Google Scholar 

  82. Barry, A. L., Jones, R. N. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, naldixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations. Antimicrobial Agents and Chemotherapy 1984, 25: 775–777.

    PubMed  Google Scholar 

  83. Hooper, D. C., Wolfson, J. S., Souza, K. S., Tung, C., McHugh, G. L., Swartz, M. N. Genetic and biochemical characterization of norfloxacin resistance inEscherichia coli. Antimicrobial Agents and Chemotherapy 1986, 29: 639–644.

    PubMed  Google Scholar 

  84. Hooper, D. C., Wolfson, J. S., Ng, E. Y., Swartz, M. N. Mechanism of action of and resistance to ciprofloxacin. American Journal of Medicine 1987, 82, Supplement 4A: 12–20.

    PubMed  Google Scholar 

  85. Gellert, M. DNA topoisomerases. Annual Review of Biochemistry 1981, 50: 879–910.

    Article  PubMed  Google Scholar 

  86. Wang, J. C. DNA topoisomerases. Annual Review of Biochemistry 1985, 54: 655–697.

    Article  Google Scholar 

  87. Wolfson, J. S., Hooper, D. C. Mechanisms of action of and resistance to quinolone antimicrobial agents. In: Wolfson, J. S., Hooper, D. C. (ed.): Quinolone antimicrobial agents. American Society for Microbiology, Washington, DC, 1989, p. 5–34.

    Google Scholar 

  88. Sugino, A., Peebles, C. L., Kruezer, K. N., Cozzarelli, N. R. Mechanism of action of nalidixic acid: purification ofEscherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proceedings of the National Academy of Sciences of the USA 1977, 74: 4767–4771.

    PubMed  Google Scholar 

  89. Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T., Tomizawa, J. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proceedings of the National Academy of Sciences of the USA 1977, 74: 4772–4776.

    PubMed  Google Scholar 

  90. Wolfson, J. S., Hooper, D. C., Ng, E. Y., Souza, K. S., McHugh, G. L., Swartz, M. N. Antagonism of wildtype and resistantEscherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers. Antimicrobial Agents and Chemotherapy 1987, 31: 1861–1863.

    PubMed  Google Scholar 

  91. Robillard, N. J., Scarpa, A. L. Genetic and physiological characterization of ciprofloxacin resistance inPseudomonas aeruginosa PAO. Antimicrobial Agents and Chemotherapy 1988, 32: 535–539.

    PubMed  Google Scholar 

  92. Yoshida, H., Kojima, T., Yamagishi, J., Nakumura, S. Quinolone-resistance mutations of thegyrA gene ofEscherichia coli. Molecular and General Genetics 1988, 211: 1–7.

    Article  PubMed  Google Scholar 

  93. Horowitz, D. S., Wang, J. C. Mapping the active site tyrosine ofEscherichia coli DNA gyrase. Journal of Biological Chemistry 1987, 262: 5339–5344.

    PubMed  Google Scholar 

  94. Swanberg, S. L., Wang, J. C. Cloning and sequencing of theEscherichia coli gyrA gene coding for the A subunit of DNA gyrase. Journal of Molecular Biology 1987, 197: 729–736.

    Article  PubMed  Google Scholar 

  95. Inoue, S., Ohue, T., Yamagishi, J., Nakamura, S., Shimizu, M. Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids. Antimicrobial Agents and Chemotherapy 1987, 14: 240–245.

    Google Scholar 

  96. Yamagishi, J., Furutami, Y., Inoue, S., Ohue, T., Nakamura, S., Shimizu, M. New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity. Journal of Bacterialogy 1981, 148: 450–458.

    Google Scholar 

  97. Yamagishi, J., Yoshida, H., Yamayoshi, M., Nakamura, S. Nalidixic acid-resistant mutations of thegyrB gene ofEscherichia coli. Molecular and General Genetics 1986, 204: 367–373.

    Article  PubMed  Google Scholar 

  98. Smith, J. T. Awakening the slumbering potential of the 4-quinolone antibacterials. Pharmaceutical Journal 1984, 233: 299–305.

    Google Scholar 

  99. Hirai, K., Aoyama, H., Suzue, S., Irikura, T., Iyobe, S., Mitsuhashi, S. Isolation and characterization of norfloxacin-resistant mutants ofEscherichia coli K12. Antimicrobial Agents and Chemotherapy 1986, 30: 248–253.

    PubMed  Google Scholar 

  100. Nikaido, H., Vaara, M. Molecular basis of bacterial outer membrane permeability. Microbiological Reviews 1985, 49: 1–32.

    PubMed  Google Scholar 

  101. Bedard, J., Wong, S., Bryan, L. E. Accumulation of enoxacin byEscherichia coli andBacillus subtilis. Antimicrobial Agents and Chemotherapy 1987, 31: 1348–1354.

    PubMed  Google Scholar 

  102. Cohen, S. P., Hooper, D. C., Wolfson, J. S., Souza, K. S., McMurry, L. M., Levy, S. B. An endogenous active efflux of norfloxacin in susceptibleEscherichia coli. Antimicrobial Agents and Chemotherapy 1988, 32: 1187–1191.

    PubMed  Google Scholar 

  103. Burman, L. G. Apparent absence of transferable resistance to nalidixic acid in pathogenic gram-negative bacteria. Journal of Antimicrobial Chemotherapy 1977, 3: 509–516.

    PubMed  Google Scholar 

  104. Munshi, M. H., Haider, K., Rahaman, M. M., Sack, D. A., Ahmed, Z. U., Morshed, M. G. Plasmid-mediated resistance to nalidixic acid inShigella dysenteriae type 1. Lancet 1987, ii: 419–421.

    Article  Google Scholar 

  105. Hane, M. W., Wood, T. H. Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. Journal of Bacteriology 1969, 99: 238–241.

    PubMed  Google Scholar 

  106. Foulds, J. tolF locus inEscherichia coli: chromosomal location and relationship of locicmlB andtolD. Journal of Bacteriology 1976, 128: 604–608.

    PubMed  Google Scholar 

  107. Nakamura, S., Inoue, S., Simizu, M., Iyobe, S., Mitsuhashi, S. Inhibition of conjugal transfer of R plasmids by pipemidic acid and related compounds. Antimicrobial Agents and Chemotherapy 1976, 10: 779–785.

    PubMed  Google Scholar 

  108. Burman, L. G. R-plasmid tranfer and its response to nalidixic acid. Journal to Bacteriology 1977, 131: 76–81.

    Google Scholar 

  109. Weisser, J., Wiedemann, B. Elimination of plasmids by new 4-quinolones. Antimicrobial Agents and Chemotherapy 1985, 28: 700–702.

    PubMed  Google Scholar 

  110. Miller, R. V., Scurlock, T. R. DNA gyrase (topoisomerase II) fromPseudomonas aeruginosa. Biochemical and Biophysical Research Communications 1983, 110: 694–700.

    Article  PubMed  Google Scholar 

  111. Inoue, Y., Sato, K., Fujii, T., Hirai, K., Inoue, M., Iyobe, S., Mitsuhashi, S. Some properties of subunits of DNA gyrase fromPseudomonas aeruginosa PAOl and its nalidixic acid-resistant mutant. Journal of Bacteriology 1987, 169: 2322–2325.

    PubMed  Google Scholar 

  112. Hirai, K., Suzue, S., Irikura, T., Iyobe, S., Mitsuhashi, S. Mutations producing resistance to norfloxacin inPseudeomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1987, 31: 582–586.

    PubMed  Google Scholar 

  113. Rella, M., Haas, D. Resistance ofPseudomonas aeruginosa PAO to nalidixic acid and low levels of β-lactam antibiotics: mapping of chromosomal genes. Antimicrobial Agents and Chemotherapy 1982, 22: 242–249.

    PubMed  Google Scholar 

  114. Hooper, D. C., Wolfson, J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrobial Agents and Chemotherapy 1985, 28: 716–721.

    PubMed  Google Scholar 

  115. Michea-Hamzehpour, M., Auckenthaler, R., Regamy, R., Pechere, J.-C. Resistance occurring after fluoroquinolone therapy of experimentalPseudomonas aeruginosa peritonitis. Antimicrobial Agents and Chemotherapy 1987, 31: 1803–1808.

    PubMed  Google Scholar 

  116. Bayer, A. S., Hirano, L., Yih, J. Development of β-lactam resistance and increased quinolone MICs during therapy of experimentalPseudomonas aeruginosa endocarditis. Antimicrobial Agents and Chemotherapy 1988, 32: 231–235.

    PubMed  Google Scholar 

  117. Sanders, C. C., Sanders, W. E., Goering, R. V., Werner, V. Selection of multiple antibiotic resistance by quinolones, β-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrobial Agents and Chemotherapy 1984, 26: 797–801.

    PubMed  Google Scholar 

  118. Gutmann, L., Billot-Klein, D., Williamson, R., Goldstein, F. W., Mounier, J., Acar, J. F., Collatz, E. Mutation ofSalmonella paratyphi A conferring cross-resistance to several groups of antibiotics by decreased permeability and loss of invasiveness. Antimicrobial Agents and Chemotherapy 1988, 32: 195–201.

    PubMed  Google Scholar 

  119. Smith, J. T., Ratcliffe, N. T. Einfluß von pH-Wert und Magnesium auf die antibakterielle Aktivität von Chinolonpraparaten. Infection 1986, 14, Supplement 1: 31–35.

    Article  Google Scholar 

  120. van Saene, J. J. M., van Saene, H. K. F., Lerk, C. F. Inactivation of quinolone by feces. Journal of Infectious Diseases 1986, 153: 999–1000.

    PubMed  Google Scholar 

  121. Zervos, M. J., Bacon, A. E., Evans, J., Patterson, J. E., Schaberg, D. R., Kauffman, C. A. Enterococcal superinfection in patients treated with ciprofloxacin. Journal of Antimicrobial Chemotherapy 1988, 21: 113–115.

    Google Scholar 

  122. Goldstein, E. J. C., Citron, D. M., Corrado, M. L. Effect of inoculum size on in vitro activity of norfloxacin against fecal anaerobic bacteria. American Journal of Medicine 1987, 82, Supplement 6B: 84–87.

    Article  Google Scholar 

  123. Aoyama, H., Sato, K., Kato, T., Mitsuhashi, S. Norfloxacin resistance in a clinical isolate ofEscherichia coli. Antimicrobial Agents and Chemotherapy 1987, 31: 1640–1641.

    PubMed  Google Scholar 

  124. Daikos, G. L., Lolans, V. T., Jackson, G. G. Alterations in outer membrane proteins ofPseudomonas aeruginosa associated with selected resistance to quinolones. Antimicrobial Agents and Chemotherapy 1988, 32: 785–787.

    PubMed  Google Scholar 

  125. Aoyama, H., Sato, K., Fujii, T., Fujimaki, K., Inouse, M., Mitsuhashi, S. Purification ofCitrobacter freundii DNA gyrase and inhibition by quinolones. Antimicrobial Agents and Chemotherapy 1988, 32: 104–109.

    PubMed  Google Scholar 

  126. Sanders, C. C., Watanakunakorn, C. Emergence of resistance toβ-lactams, aminoglycosides, and quinolones during combination therapy for infection due toSerratia marcescens. Journal of Infectious Diseases 1986, 153: 617–619.

    PubMed  Google Scholar 

  127. Milatovic, D., Braveny, I. Development of resistance during antibiotic therapy. European Journal of Clinical Microbiology 1987, 6: 234–244.

    PubMed  Google Scholar 

  128. Rylander, M., Norrby, S. R., Svard, R. Norfloxacin versus co-trimoxazole for treatment of urinary tract infections in adults: microbiological results of a co-ordinated multicentre study. Scandinavian Journal of Infectious Diseases 1987, 19: 551–557.

    PubMed  Google Scholar 

  129. Kresken, M., Weidemann, B. Development of resistance to nalidixic acid and the fluoroquinolones after introduction of norfloxacin and ofloxacin. Antimicrobial Agents and Chemotherapy 1988, 32: 1285–1288.

    PubMed  Google Scholar 

  130. Tsukamura, M., Nakamura, E., Yoshi, S., Amano, H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. American Review of Respiratory Diseases 1985, 131: 352–356.

    Google Scholar 

  131. Glupczynski, Y., Labbe, M., Burette, A., Delmee, M., Avesane, V., Bruck, C. Treatment failure of ofloxacin inCampylobacter pylori infection. Lancet 1987, i: 1096.

    Article  Google Scholar 

  132. Scully, B.E., Neu, H.C., Parry, M.F., Mandell, W. Oral ciprofloxacin therapy of infections due toPseudomonas aeruginosa. Lancet 1986, i: 819–822.

    Article  Google Scholar 

  133. Follath, F., Bindschedler, M., Wenk, M., Frei, R., Stalder, H., Reber, H. Use of ciprofloxacin in the treatment ofPseudomonas aeruginosa infections. European Journal of Clinical Microbiology 1986, 5.: 236–240.

    PubMed  Google Scholar 

  134. Giamerellou, H., Galanakis, N., Dendrinos, C., Stefanou, J., Daphnis, E., Daikos, G. K. Evaluation of ciprofloxacin in the treatment ofPseudomonas aeruginosa infections. European Journal of Clinical Microbiology 1986, 5: 232–235.

    PubMed  Google Scholar 

  135. Shalit, I., Stutman, H. R., Marks, M. I., Chatrand, S. A., Hilman, B. C. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. American Journal of Medicine 1987, 82, Supplement 4A: 174–179.

    PubMed  Google Scholar 

  136. Gilbert, D. N., Tice, A. D., Marsh, P. K., Craven, P. C., Preheim, L. C. Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gramnegative bacilli. American Journal of Medicine 1987, 82, Supplement 4A: 254–258.

    Article  PubMed  Google Scholar 

  137. Wolff, M., Bure, A., Pathe, J. P., Pangon, B., Regnier, B., Rouger-Barbier, D., Vachon, F. Evolution des resistances bacteriennes a la pefloxacine dans le service de reanimation de l'hopital Claude Bernard. In: Pocidalo, J. J., Vachon, F., Regnier, B. (ed.): Les nouvelles quinolones. Editions Arnette, Paris, 1985, p. 213–226.

    Google Scholar 

  138. Mulligan, M. E., Ruane, P. J., Johnston, L., Wong, P., Wheelock, J. P., MacDonald, K., Reinhardt, J. F., Johnson, C. C. et al.: Ciprofloxacin for eradication of methicillin-resistantStaphylococcus aureus infection. American Journal of Medicine 1987, 82, Supplement 4A: 215–219.

    PubMed  Google Scholar 

  139. Scully, B. E., Nakatomi, M., Ores, C., Davidson, S., Neu, H. C. Ciprofloxacin therapy in cystic fibrosis. American Journal of Medicine 1987, 82, Supplement 4A: 196–201.

    PubMed  Google Scholar 

  140. Maesen, F. P. V., Davies, B. I., Teengs, J. P. Pefloxacin in acute exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 1985, 16: 379–388.

    PubMed  Google Scholar 

  141. Smith, G. M., Leyland, M. J., Garrel, I. D., Geddes, A. M. Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of the febrile neutropenic patient. Journal of Antimicrobial Chemotherapy 1986, 18, Supplement D: 165–174.

    Google Scholar 

  142. Murphy, P. G., Ferguson, W. P. Corynebacterium jeikeium. Journal of Antimicrobial Chemotherapy 1987, 20: 922.

    PubMed  Google Scholar 

  143. Goldstein, E. J. C., Alpert, M. L., Najem, A., Eng, R. H.K., Ginsburg, B. P., Kahn, R. M., Cherubin, C. E. Norfloxacin in the treatment of complicated and uncomplicated urinary tract infections. A comparative multicenter trial. American Journal of Medicine 1987, 82, Supplement 6B: 65–69.

    Article  Google Scholar 

  144. Wagenvoort, J. H. T., Van Der Willigen, A. H., Van Vliet, H. J. A., Michel, M.F. Resistance ofNeisseria gonorrhoeae to enoxacin. Journal of Antimicrobial Chemotherapy 1986, 18: 429.

    Google Scholar 

  145. Chapman, S. T., Speller, D. C. E., Reeves, D. S. Resistance to ciprofloxacin. Lancet 1985, i: 39.

    Article  Google Scholar 

  146. Corrado, M. L., Grad, C., Sabbaj, J. Norfloxacin in the treatment of urinary tract infections in men with and without identifiable urologic complications. American Journal of Medicine 1987, 82, Supplement 6B: 70–74.

    Article  PubMed  Google Scholar 

  147. Desplaces, N., Gutmann, L., Carlet, J., Guibert, J., Acar, J. F. The new quinolones and their combination with other agents for therapy of severe infections. Journal of Antimicrobial Chemotherapy 1986, 17, Supplement A: 25–39.

    PubMed  Google Scholar 

  148. Cheng, A. F., Li, M.K.W., Ling, T.K.W., French, G. L. Emergence of ofloxacin-resistantCitrobacter freundii andPseudomonas maltophilia after ofloxacin therapy. Journal of Antimicrobial Chemotherapy 1987, 20: 283–292.

    Google Scholar 

  149. Scully, B. E., Neu, H. C. Oral ciprofloxacin therapy of infection caused by multiply resistant bacteria other thanPseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 1986, 18, Supplement D: 179–185.

    Google Scholar 

  150. Guibert, J., Destree, D., Konopka, C., Acar, J. Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria. European Journal of Clinical Microbiology 1986, 5: 247–248.

    PubMed  Google Scholar 

  151. Eron, L. J., Harvey, L., Hixon, D. L., Poretz, D. M. Ciprofloxacin therapy of infections caused byPseudomonas aeruginosa and other resistant bacteria. Antimicrobial Agents and Chemotherapy 1985, 27: 308–310.

    Google Scholar 

  152. Ogle, J. W., Reller, L. B., Vasil, M. L. Development of resistance inPseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe. Journal of Infectious Diseases 1988, 157: 743–748.

    PubMed  Google Scholar 

  153. Moorhouse, E. C., Clarke, P. C. Efficacy of ofloxacin in the treatment of lower respiratory tract infections in general practice. Journal of Antimicrobial Chemotherapy 1988, 22, Supplement C: 135–138.

    Google Scholar 

  154. Ryan, J. L., Berenson, C. S., Greco, T. P., Mangi, R. J., Sims, M., Thornton, G. F., Andriole, V. T. Oral ciprofloxacin in resistant urinary tract infections. American Journal of Medicine 1987, 82, Supplement 4A: 303–306.

    Article  Google Scholar 

  155. Goldstein, E. J. C., Kahn, R. M., Alpert, M. L., Ginsberg, B. P., Greenway, F. L., Citron, D. M. Ciprofloxacin versus cinoxacin therapy of urinary tract infections. A randomized, double-blind trial. American Journal of Medicine 1987, 82, Supplement 4A: 284–287.

    PubMed  Google Scholar 

  156. Cox, C. E., McCabe, R. E., Grad, C. Oral norfloxacin versus parenteral treatment of nosocomial urinary tract infection. American Journal of Medicine 1987, 82, Supplement 6B: 59–64.

    Article  Google Scholar 

  157. Esposito, S., Galante, D., Barba, D., Bianchi, W., Gagliardi, R., Giusti, R. Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver disease. Infection 1988, 16, Supplement 1: 57–61.

    Article  Google Scholar 

  158. Stein, G. E., Mummaw, N., Goldstein, E. J. C., Boyko, E. J., Reller, L. B., Kurtz, T. O., Miller, K., Cox, C. E. A multicenter comparative trial of three-day norfloxacin vs. ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections. Archives of Internal Medicine 1987, 47: 1760–1762.

    Article  Google Scholar 

  159. Blaser, J., Stone, B. B., Groner, M. C., Zinner, S. H. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrobial Agents and Chemotherapy 1987, 31: 1054–1060.

    PubMed  Google Scholar 

  160. Van der Auwera, P. Interaction of gentamicin, dibekain, netilmicin and amikacin with various penicillins, cephalosporins, minocycline, and new fluoroquinolones againstEnterobacteriaceae andPseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 1985, 16: 581–587.

    PubMed  Google Scholar 

  161. Moody, J. A., Gerding, D. N., Peterson, L. R. Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods. American Journal of Medicine 1987, 82, Supplement 4A: 44–54.

    Article  Google Scholar 

  162. Michea-Hamzehpour, M., Pechere, J.-C., Marchou, B., Auckenthaler, R. Combination therapy: a way to limit emergence of resistance? American Journal of Medicine 1986, 80, Supplement 6B: 138–142.

    Article  PubMed  Google Scholar 

  163. Bamberger, D. M., Peterson, L. R., Gerding, D. N., Moody, J. A., Fasching, C. E. Ciprofloxacin, azlocillin, ceftizoxime, and amikacin alone and in combination against gram-negative bacilli in an infected chamber model. Antimicrobial Agents and Chemotherapy 1987, 18: 51–63.

    Google Scholar 

  164. Fass, R. J., Helsel, V. L. In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs. Antimicrobial Agents and Chemotherapy 1987, 31: 1457–1460.

    PubMed  Google Scholar 

  165. Thauvin, C., Lemeland, J.-F., Humbert, G., Fillastre, J.-P. Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistantStaphylococcus aureus. Antimicrobial Agents and Chemotherapy 1988, 32: 919–921.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Disease Unit, Medical Services, Massachusetts General Hospital and Harvard Medical School, 02114, Boston, Massachusetts, USA

    J. S. Wolfson

Authors
  1. J. S. Wolfson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wolfson, J.S. Quinolone antimicrobial agents: Adverse effects and bacterial resistance. Eur. J. Clin. Microbiol. Infect. Dis. 8, 1080–1092 (1989). https://doi.org/10.1007/BF01975175

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01975175

Keywords

Search

Navigation